GREY:ICOTF - Post by User
Post by
gainwidpatienceon Jul 09, 2018 10:55am
![](https://assets.stockhouse.com/kentico-cms/0338-00/images/Sprite.svg#id_Post_Views_Icon)
139 Views
Post# 28287539
Bertilimumab License - Benefits to ICO!!!!
Bertilimumab License - Benefits to ICO!!!!iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that Immune Pharmaceuticals (IMMUNE) has licensed Bertilimumab (iCo-008) for systemic uses, pursuant to an option agreement previously announced in December 2010. iCo may receive US $32 million in milestone consideration for the license, plus royalties. iCo retains worldwide exclusive rights to all ocular applications, including a number of sight-threatening diseases.